Syn­dax inks a $350M roy­al­ty deal; FDA push­es back de­ci­sion on Organon’s eczema drug

Plus, news about Merus, Su­per­nus and Ver­ri­ca:

Syn­dax Phar­ma­ceu­ti­cals’ $350M deal with Roy­al­ty Phar­ma: The agree­ment is based on US sales …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.